Selective Anticancer Therapy Exploits Cancer Microenvironment's Increased ROS Production

Strategic Insights -

Researchers at the University of Buenos Aires, Argentina, have identified a novel approach to targeting cancer cells by leveraging the microenvironment's increased reactive oxygen species (ROS) production. By developing a chimeric promoter that responds to ROS fluctuations, they created a gene therapy that selectively inhibits cancer cell growth in vitro and in vivo.

Key Takeaways:

  • The researchers constructed a chimeric promoter that combines ROS-response motifs from the VEGF and Egr-1 gene promoters, which exhibited a high inducible response to exogenous H2O2.
  • The chimeric promoter drove the expression of the thymidine kinase (TK) gene, followed by gancyclovir (GCV) administration, resulting in the inhibition of human colorectal cancer and melanoma cell growth.
  • Electrotransfer of the TK gene combined with GCV administration exerted a potent therapeutic effect on established tumors, and this response was improved when combined with chemotherapeutic drugs.
  • The study demonstrates that a pro-oxidant state can be exploited to develop new selective gene therapeutics for cancer.

Statistics:

  • 1355-1364: The page numbers of the study published in Molecular Therapy.
  • 8: The volume number of the journal Molecular Therapy where the study was published.
  • 2009: The year when the study was published.
  • 9TH Flr: The floor number of the building where the publisher of Molecular Therapy is located.
  • 75 Varick St: The street address of the publisher's location.
  • 10013-1917: The zip code and postal code of the publisher's location.
  • C1405BWE: The postal code of the University of Buenos Aires, IIBBA, and Laboratory Molecular & Cellular Therapy.

Sources:

  • "Suppression of Cancer Growth by Nonviral Gene Therapy Based on a Novel Reactive Oxygen Species-responsive Promoter." Molecular Therapy, vol. 17, no. 8, 2009, pp. 1355-1364, doi: 10.1038/mt.2009.174.
  • O.L. Podhajcer, University of Buenos Aires, CONICET, IIBBA, Laboratory Molecular & Cellular Therapy, Foundation Institute Leloir, Av Patricias Argentinas 435, C1405BWE, Buenos Aires, DF, Argentina.
  • Nature Publishing Group, 75 Varick St., 9TH Flr, New York, NY 10013-1917, USA.